Baseline characteristics of the study participants
| Healthy controls (n=30) | COVID-19 patients (n=40) | |||
| Total | With neurological symptoms at 4 weeks (n=22) | Without neurological symptoms at 4 weeks (n=18) | ||
| Age, mean±SD (years) | 45.6±14.3 | 45.4±13.1 | 48.3±13.1 | 41.8±12.5 |
| Gender, no. (F/M) | 14/16 | 18/22 | 10/12 | 8/10 |
| Time from diagnosis, mean (SD) (months) | – | 3.7±1.5 | 3.8±1.3 | 3.6±1.7 |
| NICE-Q total score at 4 weeks, median (IQR) | – | 3.5 (1.0–6.8) | 6.0 (4.8–8.0) | 0.5 (0–2.3) |
| NICE-Q neurological score at 4 weeks, median (IQR) | – | 1.0 (0–2.0) | 2.0 (1.8–3.0) | – |
| NICE-Q total score at 12 weeks, median (IQR) | – | 2.0 (0–3.0) | 3.0 (2.5–4.0) | 0 (0–0) |
| NICE-Q neurological score at 12 weeks, median (IQR) | – | 0 (0–1.5) | 1.0 (0.5–2.0) | – |
| DN4 score, median (IQR) | – | 0 (0–0) | 0 (0–4) | – |
| FM-Q score, median (IQR) | – | 6.0 (2.0–11.0) | 10.0 (5.8–12.0) | 2.5 (0.8–6.5) |
DN4, Douleur Neuropathique 4; F, female; FM-Q, Fibromyalgia questionnaire; M, male; NICE-Q, National Institute for Health and Care Excellence long COVID questionnaire.